Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Haloperidol vs. Risperidone in the Treatment of Aggression in Psychotic Inmates

This study has been terminated.
Janssen Pharmaceutica N.V., Belgium
Information provided by:
UConn Health Identifier:
First received: September 12, 2005
Last updated: October 12, 2006
Last verified: May 2005
This study examines the efficacy of haldol versus risperdal in the treatment of aggression in psychotic prison inmates. It is hypothsized that risperdal will be more effective in decreasing aggression than haldol.

Condition Intervention
Drug: risperidone

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Efficacy of Risperidone Versus Haloperidol in the Treatment of Aggression and Hostility in Psychotic Inmates

Resource links provided by NLM:

Further study details as provided by UConn Health:

Study Start Date: July 2002
Estimated Study Completion Date: April 2004

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both

Inclusion Criteria:age 18 or over, psychotic disorder diagnosed on SCID, inmate at correctional facility for at least 2 weeks -

Exclusion Criteria: active withdrawal from substances of abuse, non-psychotic individuals, pregnant women, people unable to give informed consent, patients on mood stabilizers

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00203775

United States, Connecticut
University of connecticut health center
Farmington, Connecticut, United States, 06030
Sponsors and Collaborators
University of Connecticut
Janssen Pharmaceutica N.V., Belgium
Principal Investigator: catherine f lewis, md UConn Health
  More Information Identifier: NCT00203775     History of Changes
Other Study ID Numbers: RIS-USA-269  IRB Project Number 01-250  RIS-USA-T255 
Study First Received: September 12, 2005
Last Updated: October 12, 2006
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Behavioral Symptoms
Haloperidol decanoate
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Dopamine Antagonists
Dopamine Agents
Autonomic Agents
Peripheral Nervous System Agents
Gastrointestinal Agents
Anti-Dyskinesia Agents processed this record on October 21, 2016